2 nd European Breast Cancer Conference: A colloquio con Antony Howell

Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467.

Dixon J.M. , Nicholson R.I. , Robertson J.F.R. : Comparison of the short term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer. In: 2nd European Breast Cancer Conference, Abstract Book, A161.

Robertson J.F.R. , Howell A. , DeFriend D. : Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen-resistant breast cancer. Breast 1997; 6(4): 186–189.

Robertson J. , Buzdar A. , Nabholtz J. : Anastrazole (Arimidex TM) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women. Prospective combined analysis from two international trials. In: 2nd European Breast Cancer Conference - Abstract Book, A219.

Baum M The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women: baseline patient and tumour characteristics. In: 2nd European Breast Cancer Conference - Abstract Book, A139.

Jonat W Zoladex TM (Goserelin) vs CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer: first efficacy results from the ZEBRA study. In: 2nd European Breast Cancer Conference - Abstract Book, A132.

Gail M.H. , Brinton L.A. , Byar D.P. : Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–1886.

Fisher B. , Costantino J.P. , Wickerham D.L. : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371–1388.

Cauley J.A. , Lucas F.L. , Kuller L.H. : Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996; 276: 1404–1408.

Cummings S.R. , Eckert S. , Krueger K.A. : The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 282: 2124.

Jordan V.C. , Glusman J.E. , Eckert S. : Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat 1998; 50: 227(ABS).

Chlebowski R.T. , Collyar D.E. , Somerfield M.R. : American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999; 17: 1939–1955.